Revance Therapeutics Inc  

(Public, NASDAQ:RVNC)   Watch this stock  
Find more results for RVNC
33.60
-0.90 (-2.61%)
After Hours: 33.60 0.00 (0.00%)
Jan 16, 4:29PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.30 - 34.95
52 week 18.00 - 37.45
Open 34.60
Vol / Avg. 377,179.00/918,191.00
Mkt cap 1.04B
P/E     -
Div/yield     -
EPS -3.81
Shares 30.97M
Beta 1.62
Inst. own 101%
Dec 5, 2017
Revance Therapeutics, Inc. - Special Call - Webcast
Nov 2, 2017
Q3 2017 Revance Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -40868.00% -29756.67%
Operating margin -40954.67% -29405.00%
EBITD margin - -25903.67%
Return on average assets -69.02% -37.18%
Return on average equity -81.56% -41.49%
Employees 131 -
CDP Score - -

Address

7555 Gateway Blvd
NEWARK, CA 94560-1152
United States - Map
+1-510-7423400 (Phone)
+1-510-7423401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

Officers and directors

Angus Charles Russell Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
L. Daniel Browne Co-Founder, President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Lauren P. Silvernail Chief Financial Officer, Chief Business Officer
Age: 58
Bio & Compensation  - Reuters
Abhay Joshi Ph.D. Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Todd E. Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics
Age: 45
Bio & Compensation  - Reuters
Mark J. Foley Director
Age: 51
Bio & Compensation  - Reuters
Robert F. Byrnes Independent Director
Age: 72
Bio & Compensation  - Reuters
Julian S. Gangolli Independent Director
Age: 59
Bio & Compensation  - Reuters
Phyllis I. Gardner M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Philip J. Vickers Independent Director
Age: 56
Bio & Compensation  - Reuters